Previous close | 1.4900 |
Open | 1.6000 |
Bid | 0.0000 |
Ask | 4.8000 |
Strike | 520.00 |
Expiry date | 2024-06-21 |
Day's range | 1.4900 - 1.7500 |
Contract range | N/A |
Volume | |
Open interest | 376 |
Sanofi (SNY) and Regeneron's (REGN) Dupixent is poised to be the first medicine for adolescents with inadequately controlled CRSwNP, if approved by the FDA.
If approved, Dupixent would be the first treatment in the U.S. indicated for adolescents aged 12-17 years with inadequately controlled CRSwNP, a condition driven in part by underlying type 2 inflammation that obstructs the sinuses and nasal passages and can lead to a loss of sense of smell Current treatment options for adolescents with CRSwNP leave many patients with uncontrolled disease and often result in the recurrence of nasal polyps TARRYTOWN, N.Y. and PARIS, May 13, 2024 (GLOBE NEWSWIRE) -
Key Insights Institutions' substantial holdings in Regeneron Pharmaceuticals implies that they have significant...